A Phase 4 interventional study of Desflurane and propofol in Coronary Artery Bypass Graft Redo and General Anesthetic Drug Adverse Reaction, sponsored by Huazhong University of Science and Technology. Status unknown at 1 site in China. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-08-11.
Sponsored by Huazhong University of Science and Technology · Phase 4, Interventional, and Prevention
This study is to assess the effect of desflurane on myocardial function in patents who underwent coronary artery bypass grafting.
Desflurane, one of the third-generation inhaled anesthetics, is introduced in clinical practice in 1990s. Decades of clinical use has provided evidence for desflurane's safe and efficacious use as a general anesthetic. Compared with other volatile anesthestics, it has several characteristics: lower blood and lipid solubility, more stable in vitro and the lowest in vivo metabolism. Its particular low fat solubility properties promote rapid equilibration and rapid elimination at the end of anesthesia which reduces slow compartment accumulation and promotes predictable emergence, early extubation, and the ability to rapidly transfer patients from the operating room to the recovery unit. In addition, several investigations found that patients with desflurane anesthesia recovered their protective airway reflexes and awakened to a degree sufficient to minimize the stay in the high dependency recovery area.
A burgeoning body of investigations has shown that desflurane can directly act on myocardial and vascular functions. Desflurane has coronary vasodilative effects in in situ canine hearts which is comparable to sevoflurane does. Although it is controversial regarding to the effect of desflurane on myocardial excitation-contraction coupling and electrophysiologic behavior, a elaborated study found desflurane induced a positive inotropic effect in rat myocardium in vitro compared with isoflurane. A recent study suggested that desflurane decreased right ventricular contractility much less and maintained the right over left pressures ratio at more favorable values compared with sevoflurane. Furthermore, substantial investigations found that clinically relevant concentration desflurane preconditioning or postconditioning could protect myocardium from ischemia-reperfusion in mammalian animal models or isolated human cardiac tissues. However, it is unclear whether desflurane can provide protection for patients with coronary artery disease. Therefore, this study is designed to investigate the effect of desflurane on myocardial function in patents who underwent coronary artery bypass grafting.
437 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 76 are open to participants now.
This study's planned enrollment of 60 is below the median of 103 across 255 interventional studies indexed under Drug-Related Side Effects and Adverse Reactions.
Browse Drug-Related Side Effects and Adverse Reactions studies →Huazhong University of Science and Technology is the lead sponsor of 241 studies on the registry; 60 are open to participants now.
Counted across the registry records on this site, refreshed daily.
-
Exclusion Criteria:
desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)
Drug: Desflurane · Drug: sufentanil
intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).
Drug: propofol · Drug: sufentanil
desflurane (7%-8% end-tidal concentration)
Also known as: brand names：Baxter, serial numbers and code names：not available yet
propofol (TCI:3.5-4.0μg/min)
Also known as: brand name：Diprivan, serial numbers and code names：not available yet
TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
Also known as: brand name: Yichang Humanwell pharmaceutical co.,LTD, serial numbers and code names: not available yet
Serum Concentration of cTnI
at the begingineg of the surgery,immediately after surgery,4 hours after the surgery, 8 hours after the surgery, 12 hours after the surgery, 24 hours after the surgery
Time frame: 48 hours
Continuous Monitoring of ECG
participants will be followed for the duration of hospital stay, an expected average of 5 weeks.ECG incidents such as tachycardia, bradycardia, premature ventricualr contraction and ST segment changes will be monitored and recorded.
Time frame: participants will be followed for the duration of hospital stay, an expected average of 5 weeks
Incidence of segmental wall motion
Incidence of segmental wall motions will be monitored during the surgery, an expected average of 4 hours.
Time frame: Incidence of segmental wall motions will be monitored during the surgery, an expected average of 4 hours.
This study is status unknown, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Drug-Related Side Effects and Adverse Reactions→
Huazhong University of Science and Technology